Data in Brief (Dec 2022)
Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
- Leonie Müller-Jensen,
- Sarah Zierold,
- Judith M Versluis,
- Wolfgang Boehmerle,
- Petra Huehnchen,
- Matthias Endres,
- Raphael Mohr,
- Annette Compter,
- Christian U Blank,
- Tim Hagenacker,
- Friedegund Meier,
- Lydia Reinhardt,
- Anja Gesierich,
- Martin Salzmann,
- Jessica C Hassel,
- Selma Ugurel,
- Lisa Zimmer,
- Patricia Banks,
- Lavinia Spain,
- Jennifer A Soon,
- Tomohiro Enokida,
- Makoto Tahara,
- Katharina C Kähler,
- Ruth Seggewiss-Bernhardt,
- Catriona Harvey,
- Georgina V Long,
- Florian Schöberl,
- Louisa von Baumgarten,
- Thomas Hundsberger,
- Max Schlaak,
- Lars E French,
- Samuel Knauss,
- Lucie M Heinzerling
Affiliations
- Leonie Müller-Jensen
- Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany
- Sarah Zierold
- SERIO Side Effects Registry Immunooncology, Germany; Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilian Universität Munich, Frauenlobstr. 9-11, München 80337, Germany
- Judith M Versluis
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
- Wolfgang Boehmerle
- Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany
- Petra Huehnchen
- Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany
- Matthias Endres
- Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany; NeuroCure Cluster of Excellence, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin 10117, Germany; Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin 10117, Germany; German Center for Neurodegenerative Diseases (DZNE), Partner Site Berlin, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany
- Raphael Mohr
- Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, , Augustenburger Platz 1, Berlin 13353, Germany
- Annette Compter
- Department of Neuro-Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
- Christian U Blank
- Department of Medical Oncology, Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands
- Tim Hagenacker
- Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Hufelandstr. 55, Essen 45147, Germany
- Friedegund Meier
- Department of Dermatology, Skin Cancer Center at the University Cancer Center Dresden and National Center for Tumor Diseases, TU Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
- Lydia Reinhardt
- Department of Dermatology, Skin Cancer Center at the University Cancer Center Dresden and National Center for Tumor Diseases, TU Dresden, University Hospital Carl Gustav Carus, Dresden, Germany
- Anja Gesierich
- Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
- Martin Salzmann
- Department of Dermatology and National Center for Tumor Diseases (NCT), Skin Cancer Center, University Hospital Heidelberg, Heidelberg, Germany
- Jessica C Hassel
- Department of Dermatology and National Center for Tumor Diseases (NCT), Skin Cancer Center, University Hospital Heidelberg, Heidelberg, Germany
- Selma Ugurel
- Department of Dermatology, Venerology und Allergology, University Hospital Essen, Essen, Germany
- Lisa Zimmer
- Department of Dermatology, Venerology und Allergology, University Hospital Essen, Essen, Germany
- Patricia Banks
- Andrew Love Cancer Centre, University Hospital Geelong, Geelong, Australia
- Lavinia Spain
- Medical Oncology Department, Peter MacCallum Cancer Center, Melbourne, Australia
- Jennifer A Soon
- Medical Oncology Department, Peter MacCallum Cancer Center, Melbourne, Australia
- Tomohiro Enokida
- Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan
- Makoto Tahara
- Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa 277-8577, Japan
- Katharina C Kähler
- Department of Dermatology, Venerology and Allergology, University of Schleswig-Holstein Hospital, Campus Kiel, Germany
- Ruth Seggewiss-Bernhardt
- Department of Hematology and Oncology, Sozialstiftung Bamberg, Bamberg, Germany
- Catriona Harvey
- Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia
- Georgina V Long
- Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia
- Florian Schöberl
- Department of Neurology, Ludwig-Maximilian Universität, Marchioninistraße 15, München 83177, Germany
- Louisa von Baumgarten
- Department of Neurology, Ludwig-Maximilian Universität, Marchioninistraße 15, München 83177, Germany; Division of Neuro-Oncology, Department of Neurosurgery, Ludwig-Maximilian Universität, Marchioninistraße 15, München 83177, Germany
- Thomas Hundsberger
- Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland
- Max Schlaak
- Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany
- Lars E French
- Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilian Universität Munich, Frauenlobstr. 9-11, München 80337, Germany; Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
- Samuel Knauss
- Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin 10117, Germany; SERIO Side Effects Registry Immunooncology, Germany; Corresponding author at: Department of Neurology with Experimental Neurology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt- Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany.
- Lucie M Heinzerling
- SERIO Side Effects Registry Immunooncology, Germany; Department of Dermatology and Allergy, University Hospital, Ludwig-Maximilian Universität Munich, Frauenlobstr. 9-11, München 80337, Germany; Department of Dermatology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany
- Journal volume & issue
-
Vol. 45
p. 108649
Abstract
Over the past decade, cancer immunotherapy with immune checkpoint inhibitors (ICIs) has significantly improved the outcome of many malignancies. However, with the broad use of ICIs, neurological immune related adverse events (irAE) are increasingly recognized. ICI-induced encephalitis (ICI-iE) is a particularly severe irAE, often leading to treatment termination, long-term sequalae or death. Despite its high morbidity and mortality, data on clinical features and diagnostic criteria are limited.We aimed to define clinical, radiologic and laboratory characteristics of ICI-iE and identify factors that discriminate it from anti-leucine-rich glioma-inactivated (anti-LGI)-1 encephalitis and herpes simplex virus (HSV)-1 encephalitis – two alternative causes of encephalitis – to increase the awareness of ICI-iE and improve its diagnosis and management.To that end, we retrospectively collected 30 cases of ICI-iE that were reported to the Side Effect Registry Immuno-Oncology (SERIO) and 46 cases of anti-LGI1 encephalitis or herpes simplex virus (HSV)-1 encephalitis that presented to a large German neurological referral center (Charité Universitätsmedizin Berlin) between January 2015 and September 2021. Signs and symptoms, imaging and electroencephalogram features, laboratory findings and outcome measures were assessed using standardized case report forms as well as patients’ medical records and compared between the groups.The data reported here represents the largest primary cohort of patients with ICI-iE to date and the first comparison with other types of encephalitis. As all three disorders – ICI-iE, HSV-1 encephalitis and anti-LGI1 encephalitis – are rare neurological entities, this dataset can be used as a reference in future clinical studies on ICI-induced neurotoxicity, neurological autoimmune disorders, and central nervous system infections.
